Public Release: 

Eating peanut at an early age prevents peanut allergy in high-risk infants

King's College London

New evidence shows that the majority of infants at high-risk of developing peanut allergy are protected from peanut allergy at age 5 years if they eat peanut frequently, starting within the first 11 months of life. For many years Public Health Guidelines, Paediatricians and Allergists have recommended avoiding foods in infant's diet that cause allergies such as peanut. However, the LEAP (Learning Early About Peanut Allergy) study led by Professor Gideon Lack, King's College London, and published today in the New England Journal of Medicine, is the first study to show that consumption is an effective strategy to prevent food allergy, contradicting previous recommendations.

The incidence of food allergy has risen in recent decades, and peanut allergy now affects up to 1 in 50 school age children in the UK; the occurrence of peanut allergy has more than doubled in the last 10 years in the UK and North America. It affects between 1-3% of children in Western Europe, the USA, and Australia and in recent years has become an important cause of food allergies in African and Asian countries. Peanut allergy develops early in life, is rarely out-grown and there is currently no cure. It imposes a considerable burden, impacting negatively on quality of life for patients and their families.

The LEAP study, a randomized controlled trial, enrolled 640 children aged 4-11 months from Evelina London Children's Hospital, who were considered at high-risk of developing peanut allergy due to pre-existing severe eczema and/or egg allergy. To determine whether peanut consumption or avoidance is the most effective strategy to prevent peanut allergy, half of the children were asked to eat peanut-containing foods three or more times each week, and the other half to avoid eating peanut until 5 years of age. Adherence to peanut consumption or avoidance advice was assessed using a food frequency questionnaire at regular intervals during the study and by measuring peanut levels in the child's home environment.

Remarkably, less than 1% of children who consumed peanut as per study protocol and completed the study developed peanut allergy by 5 years of age, while 17.3% in the avoidance group developed peanut allergy. Even when considering all children enrolled - including those participants who were unable to tolerate peanut consumption (13 of the 319 children who were randomised to peanut consumption had some allergic responses to peanut during the study) - a powerful protective effect against the development of peanut allergy remains: the overall prevalence of allergy in all children asked to consume peanut was 3.2% versus 17.2% in the avoidance group. This represents a greater than 80% reduction in the prevalence of peanut allergy. Nearly all participants enrolled on the LEAP study completed the final assessment at age 5 years (98%). Importantly, the early introduction of peanut-containing foods was found to be safe and well tolerated; infants were not fed whole peanuts which carry a risk of choking in young children.

The study was therefore able to conclude that early, sustained consumption of peanut is safe and associated with a substantial and significant decrease in the development of peanut allergy in high-risk infants by the age of five. Deliberate avoidance of peanut in the first year of life is consequently brought into question as a strategy to prevent allergy.

Professor Gideon Lack, Head of Department of Paediatric Allergy, King's College London and Head of the Children's Allergy Service at Guy's and St Thomas' NHS Foundation Trust, who led the study, presented the findings at the American Academy of Allergy, Asthma and Immunology meeting (AAAAI): "This is an important clinical development and contravenes previous guidelines. Whilst these were withdrawn in 2008 in the UK and US, our study suggests that new guidelines may be needed to reduce the rate of peanut allergy in our children."

Professor Lack further noted that: "The study also excluded infants showing early strong signs of having already developed peanut allergy; the safety and effectiveness of early peanut consumption in this group remains unknown and requires further study. Parents of infants and young children with eczema and/or egg allergy should consult with an Allergist, Paediatrician, or their General Practitioner prior to feeding them peanut products."

Dr George Du Toit, consultant in Paediatric Allergy at Guy's and St Thomas' NHS Foundation Trust and honorary senior lecturer, King's College London, co-investigator of the study, said: "The next stage of our work, the LEAP-On study, will continue to monitor those children who consumed peanut to see if they remain protected against allergy even if they stop consuming peanut for 12 months. The LEAP-On study will help establish if the protection provided against the development of peanut allergy is sustained and not dependent on ongoing peanut ingestion."


Notes to editors

For further information please contact Hannah Bransden, Press Officer at King's College London, on 0207 848 3840 or email

Professor Gideon Lack will present the results of the LEAP study at the American Academy of Allergy, Asthma and Immunology (AAAI) in Houston, US and will be present at a press conference following his talk, Monday 23 February, 16:45-17:30 US Central Time.

'Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy' by Du Toit et al is published online in the journal The New England Journal of Medicine on 23 February 2015.

The study was designed and conducted by the Immune Tolerance Network (ITN), supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, and Food Allergy Research & Education

For further information about King's College London, please visit our 'King's in Brief' web page.

Evelina London Children's Hospital is part of Guy's and St Thomas' NHS Foundation Trust. For more information about Evelina London Children's Hospital please visit Evelina London treats around 55,000 children a year across hospital and community services. Facilities include 140 beds, a 20-bed paediatric intensive care unit, six operating theatres and a kidney dialysis unit. Evelina London cares for children from across south east London, and is also a regional referral centre, admitting children from all over the south east of England for highly specialist care. Evelina London isn't like other hospitals. It's only for children and young people - and it was designed by children, for children, to make every child who comes through our doors feel as safe, supported and special as possible. To support or donate to Evelina London visit or text 'Evelina' to 70800 to donate £5

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.